Galderma Reveals Long-Term Nemolizumab Data As It Prepares To Take On Dupixent

IL-31 Inhibitor On File In US And EU

 
• By Mandy Jackson
  
Different light bulb glowing in a line
Galderma is set to position nemolizumab as a unique option • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D